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Abstract
Despite evidence for the important role of oestrogens in the aetiology and pathophysiology of chronic
immune/inflammatory diseases, the previous view of an unequivocal beneficial effect of oestrogens on RA
compared with a detrimental effect on SLE has to be reconsidered. Likewise, the long-held belief that RA
remits in the majority of pregnant patients has been challenged, and shows that only half of the patients
experience significant improvement when objective disease activity measurements are applied.
Pregnancies in patients with SLE are mostly successful when well planned and monitored interdisciplina-
rily, whereas a small proportion of women with APS still have adverse pregnancy outcomes in spite of the
standard treatment. New prospective studies indicate better outcomes for pregnancies in women with rare
diseases such as SSc and vasculitis. Fertility problems are not uncommon in patients with rheumatic
disease and need to be considered in both genders. Necessary therapy, shortly before or during the
pregnancy, demands taking into account the health of both mother and fetus. Long-term effects of drugs
on offspring exposed in utero or during lactation is a new area under study as well as late effects of
maternal rheumatic disease on children.
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Introduction
Rheumatic diseases occur preferentially in women, often
during the childbearing years. The female preponderance
has raised the confirmed conviction that sex hormones
play an important role in both disease development and
course.
During pregnancy, profound changes of the hormonal
milieu take place. The increase of free steroid hormones
including glucocorticoids, progesterones and oestrogens,
induces changes in functions of immunocompetent
cells such as B cells, T cells and monocytes [1]. As a
consequence, clinical symptoms of immune-mediated
rheumatic diseases are modified related to the prevailing
pathophysiological disease process; some improve, while
others remain relatively unchanged or worsen during
pregnancy.
Pregnancy outcome may be threatened by severe
organ involvement and the presence of autoantibodies.
Rare diseases with anecdotal pregnancy experience, like
most of the vasculitides, pose problems in pregnancy
management.
Fetal and neonatal effects of maternal autoantibodies
are well known, whereas the long-term outcome of
children born to mothers with autoimmune rheumatic
disease is still insufficiently studied. Likewise, causes of
impairment of fertility in patients with rheumatic disease
need more detailed investigation, particularly in males.
This survey gives a concise overview of current basic and
clinical research into the various aspects of reproduction
in rheumatic diseases.
Sex hormones and autoimmune diseases
Immunological, epidemiological and clinical evidence
suggest that female sex hormones play an important
role in the aetiology and pathophysiology of chronic
immune/inflammatory diseases [1]. Oestrogens are gener-
ally considered as enhancers of cell proliferation and
humoral immune responses, whereas androgens have
opposite effects [1]. However, the role of oestrogens in
human autoimmune diseases has been under debate
with partly confusing and opposite conclusions because
of animal and cellular studies.
Today, important factors to be considered are the
different effects of oestrogens on their different receptors
or on different target cells, the influence of oestrogen con-
centrations (Fig. 1) and finally, opposite effects (especially
on cell proliferation) exerted by different peripheral
oestrogen metabolites in humans [2].
A preponderance of 16a-hydroxylated oestrogen
metabolites as observed in RA SF is unfavourable in syn-
ovial inflammation since these metabolites enhance cell
proliferation including that of synoviocytes [2]. In addition,
since 17b-oestradiol administered during HRT will rapidly
increase oestrone sulphate after conversion in adipose
tissue by aromatases, HRT can have pro-inflammatory
FIG. 1 Immunomodulatory effects of oestrogens. (A) Serum oestrogens in physiological concentrations are generally
implicated in maturation of Th cells (Th0) into Th1-type T cells. In pharmacological concentrations and pregnancy levels
(high), they mainly support the maturation of Th0 T cells into Th2 type T cells (and B-cell activation). (B) During pregnancy,
as serum oestrogen concentrations increase, a shift to a Th2 response is supported, therefore classical Th1-driven
diseases such as RA are mitigated (improvement in 5075%), whereas classical Th2-driven diseases such as SLE may be
negatively influenced (complications in 4070%).
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effects by providing oestrone sulphate to the inflamed RA
synovial tissue [1].
In SLE, peripheral blood mononuclear cells show an
increase in anti-dsDNA and IL-10 in response to oestro-
gen [3, 4]. Women with SLE tend to have lower levels of
DHEA, which are further reduced by treatment with pred-
nisone. In clinical trials, DHEA supplementation was help-
ful both for disease activity and for BMD in SLE patients
[5]. Oestrogen substitution in post-menopausal women
with SLE increases mild/moderate, but not severe, flares
significantly [6].
However, oral contraceptive (OCP) use is an estab-
lished risk factor for SLE [7]. This risk is particularly
elevated in women who recently started OCPs, sug-
gesting an acute effect at least in a small subgroup
of susceptible women [7]. OCPs do not increase flares
in women with established SLE that is inactive or only
moderately active [8]. In conclusion, it is now much
better established that female gonadal hormones exert
an important role in the aetiology and course of chronic
inflammatory/autoimmune diseases as epidemiological,
immunological and clinical evidence shows that menstrual
cycle, pregnancy, menopausal status and OCPs are
significant influencing factors [1].
Pregnancy and autoimmune rheumatic
diseases
Pregnancy is a state of high concentration of sex hormones
and cross-talk between mother and fetus. Throughout
pregnancy, the hormonal, biochemical and immunological
equilibrium in the mother changes related to the stage
of pregnancy. However, at all stages tolerance to
the semi-allogeneic fetus is maintained by a supportive
immunological milieu [9]. Related to the pathogenesis,
clinical symptoms of the autoimmune rheumatic diseases
vary: some improve spontaneously during gestation,
others remain active or even flare. Likewise, pregnancy
outcome is different depending on disease extent and
severity (Table 1).
RA and AS
Retrospective and some prospective studies have shown
that RA improves during pregnancy and flares after deliv-
ery. The largest prospective study from the Netherlands
assessing the effect of pregnancy on RA, and the impact
of RA on pregnancy includes >200 women at present [10].
Forty-eight per cent of the RA patients improved during
pregnancy according to the 28-joint DAS (DAS-28)-
derived EULAR response criteria, whereas 41% flared
after delivery according to reversed EULAR response
criteria [10].
Neither improvement of disease activity of RA during
pregnancy nor the post-partum flare was associated
with changes in levels of anti-citrullinated protein antibo-
dies (ACPAs) or RF [11]. However, women negative for
ACPA and RF were more likely to improve during preg-
nancy [11].
Higher disease activity during pregnancy was asso-
ciated with lower birth weight (multiple regression analysis
75 g (95% CI 142, 8.0 g) decrease in birthweight
per 1.0 increase in DAS-28). Gestational age at delivery
of patients using prednisone was significantly shorter
(38 5/7 vs 39 6/7 weeks, P= 0.006), and their delivery
more often premature (<37 weeks), 8.6% in the RA
group compared with 6.2% in the control group [12].
The pregnancy-induced amelioration of RA presents
a window of opportunity for insights into pathogenic
mechanisms in this disease. Bi-directional trafficking of
cells or DNA occurs routinely during normal pregnancy,
from fetus to mother and mother to fetus.
Microchimerism (Mc) refers to a small number of
cells (or DNA) harboured by one individual that originated
in a genetically different individual. Pregnancy has im-
munological effects both in the short term and for
the long term. Higher levels of fetal Mc were found in the
circulation of women with RA who improved during
pregnancy compared with those who did not [13].
Pregnancy also leaves a legacy for the long term as it is
now known that decades after birth fetal Mc persists in
the mother and maternal Mc in her offspring. Women with
RA who were themselves negative for HLA alleles asso-
ciated with RA risk were recently reported to harbour Mc
with RA-risk alleles significantly more often than healthy
women [14]. Thus, Mc could contribute to both health and
disease.
Among factors influencing disease activity and immuno-
logical mechanisms of fetalmaternal tolerance are
CD4+CD25+FOXP3+ Tregs. Tregs suppress immune
responses thereby preventing autoimmune disease and
supporting maternal tolerance towards the fetus. In
healthy women, the number of circulating Tregs increases
during pregnancy and declines post-partum. The same
pregnancy-related expansion of Tregs is found in patients
with RA and AS [15, 16]. However, unlike in healthy
women, Tregs of RA and AS patients are unable to sup-
press effectively the pro-inflammatory cytokine response
of T-effector cells [16].
In RA, pregnancy restores Treg function creating an
anti-inflammatory cytokine milieu in the third trimester at
the time of maximal improvement of RA disease activity
[15]. In contrast to RA, pregnancy does not substantially
alter the disease activity in AS. This was reflected
by a defective Treg function with impaired capacity to
suppress pro-inflammatory cytokines [16]. Thus, the
different clinical response of RA and AS to pregnancy
corresponded to a different response at the cellular level.
SLE
In contrast to RA, SLE often remains active or even flares
during pregnancy. There are clear differences in hormonal
and cytokine levels in SLE vs control pregnancies [17].
Data from the Hopkins Lupus Pregnancy Cohort have
shown an increase in renal flares in pregnant SLE patients
[18]. However, a Canadian prospective study found
changes in renal disease activity and deterioration in
renal function in pregnant patients similar to those
www.rheumatology.oxfordjournals.org 659
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which occur in non-pregnant patients with LN [19]. Other
studies have shown that SLE flares are not more severe in
pregnancy than in the non pregnant state [20].
The combination of high clinical activity and abnormal
serology (complement or anti-dsDNA) is most predictive
of a poor obstetric outcome [18]. Pregnancy loss is
increased when there is proteinuria, aPL, thrombocyto-
penia or hypertension at the first pregnancy visit [18].
Concerning therapy, HCQ use is desirable in preg-
nancy, as HCQ-treated pregnancies have fewer preterm
births and less severe clinical activity [21]. Prednisone, in
contrast, at high concentrations, is associated with more
diabetes, hypertension and pre-eclampsia.
The PROMISSE (predictors of pregnancy outcome:
biomarkers in antiphospholipid syndrome and systemic
lupus erythematosus) study is an ongoing prospective ob-
servational study to identify markers that predict
poor pregnancy outcome (fetal growth restriction, pre-
eclampsia, fetal or neonatal death) in patients with the
named diseases. Particular focus is on complement
activation and on angiogenic factors in predicting poor
outcome [22]. Patients are grouped as: aPL; no SLE
(goal 150, 93 recruited as of 1 September 2009); aPL
and SLE (goal 100, 42 recruited); SLE with no aPL (goal
250, 220 recruited); and neither SLE nor aPL and prior
successful pregnancies with no more than one early
miscarriage (goal 200, 154 recruited).
As of 1 September 2009, surprisingly good outcomes
are shown in all patient groups [48 (16%) of the 307 study
patients and 2 (2%) of the 117 normal delivered patients
had poor outcomes] with those with SLE and aPL faring
worst. Preliminary analyses suggest that LA, formally
defined by confirmatory tests after positive screening for
activated PTT, KCT, DRVVT and/or dilute PT, is a far
better predictor of poor outcome than is high titre aPL
and anti-b2-glycoprotein I immunoglubulin (Ig) G (IgG)
antibody; IgM and IgA antibodies are not predictive.
Neonatal lupus syndromes
Transplacental transfer of Ro/SSA antibodies can induce
neonatal lupus syndromes, either as a typical skin rash
that resolves spontaneously within 6 months after birth
or a congenital heart block (CHB) in the child.
Atrioventricular (AV) block is defined as congenital if
diagnosed in utero, at birth or within the neonatal period
(027 days after birth).
The most common presentation is an unexpected
advanced AV block in the fetus of a healthy asymptomatic
mother (85% of cases) [23]. To differentiate these blocks
into complete vs incomplete is difficult in utero. The risk
of delivering a child with complete CHB for anti-Ro/
SSA-positive mothers is 12% [23]. The risk of recurrence
is 1520%; unfortunately high dose IVIGs are not effective
in reducing this risk [24].
Other minor ECG abnormalities may be present in
infants born by anti-Ro/SSA-positive mothers [PQ interval
(time between the beginning of the atrial contraction and
the beginning of the ventral contraction) prolongation,
sinus bradycardia]. Anti-Ro/SSA antibodies do not nega-
tively affect other pregnancy outcomes [23].
APS
aPLs are associated with recurrent pregnancy losses.
Different aPL-mediated pathogenic mechanisms have
been described, such as: (i) placental thrombotic events;
(ii) placental inflammatory events following local
TABLE 1 Interaction of pregnancy and some CTDs or vasculitis
Disease
Effect of pregnancy
on disease
Risk of maternal
complications in
pregnancy
Risk for pregnancy
complications Risk for fetus/neonate
RA Improvement
in 4875%
No Moderate increase Very rare
SLE Flare in 50%
of cases
Most frequent:
haematological,
and renal
complications
Hypertension,
pre-eclampsia,
prematurity
Fetal loss, intrauterine
growth restriction, low
birthweight, neonatal
lupus
APS Aggravation Thrombosis Pre-eclampsia,
prematurity,
HELLP syndrome
Fetal loss, intrauterine
growth restriction, low
birthweight
SSc No major effect on
disease activity
Not more frequent
than outside
pregnancy
Prematurity Reduced birthweight in
premature infants
Takayasu
arteritis
Unchanged in 72%,
improvement in
20%
Progression of renal
insufficiency,
congestive
heart failure
Hypertension
in 3044%
Pre-eclampsia
in 1216%
Only at severe maternal
disease, otherwise
85% good neonatal
outcome
ANCA-positive
vasculitis
Data insufficient
to discern a
particular effect
Renal and pulmonary
disease
Pre-eclampsia,
prematurity
Fetal loss, intrauterine
growth restriction, low
birthweight
HELLP: haemolysis, elevated liver enzymes low platelet.
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complement (C0) activation; and (iii) direct aPL effect on
trophoblast cells inducing defective placentation. In two
previous investigations of placental tissue, placental
thrombosis was no more frequent in patients with APS
and recurrent miscarriage than in patients with recurrent
miscarriage who were aPL negative. There were no spe-
cific placental lesions or patterns of abnormalities charac-
teristic of the primary APS (PAPS) [25].
In a prospective study, histological and immunohisto-
chemistry analysis of term placentas or abortive materials
was carried out in 14 pregnancies of women affected by
PAPS and compared with five matched controls [26]. No
specific histological pattern or widespread inflammation
was found. Complement activation was detected for the
first time in APS placentas both in abortive specimens and
in placentas at term, but there was no relationship with
therapy or pregnancy outcome. These results suggest
that complement activation may contribute to placental
damage; however, whether it plays a key role is not
clarified.
The poor pregnancy outcome in women with APS has
been changed by therapy with anti-aggregation (low-dose
aspirin) alone or in association with anti-coagulation
(low-molecular-weight heparin) to a nearly 80% rate of
live births. However, 20% of pregnancies still experience
poor outcome despite conventional treatment. Various
treatments have been suggested after failure of conven-
tional therapy ranging from increasing the dose of
low-molecular-weight heparin, or adding either steroids,
HCQ or IVIG [27]. Recently, the Antiphospholipid
European Forum promoted a multicentre project for col-
lecting cases of pregnancy loss despite anti-aggregating
and anti-coagulation treatment in women with APS and
matched controls [28]. Preliminary results showed that
women with unsuccessful pregnancies were more likely
to be those with SLE, or with a history of thrombosis or
thrombocytopenia.
A severe complication in both SLE and APS is the
increased risk of pre-eclampsia triggered by placental
dysfunction caused by maternal endothelial cell dysfunc-
tion. Both genetic polymorphisms, dysregulation of
angiogenic factors [29] and a variety of other factors
are involved in the pathogenesis of pre-eclampsia. It
has been hypothesized that increased circulating,
soluble Fms-like tyrosine kinase (sFlt-1) contributes to
the endothelial dysfunction, hypertension and proteinuria
of pre-eclampsia. Interestingly, elevated sFlt-1 levels
have been detected in SLE pregnancies at risk for
pre-eclampsia [30].
A recent study showed that cell-free, fetal nucleic
acids (DNA and mRNA) are released by the placental
trophoblast, and are elevated in cases with manifest
pre-eclampsia [31]. Levels correlated with disease sever-
ity and were higher in early-onset than in late-onset
pre-eclampsia. Furthermore, cell-free DNA levels were
found to be elevated early in pregnancy (<24 weeks of
gestation) in those cases that subsequently developed
pre-eclampsia, but not in those with normal pregnancy
outcome.
In addition, studies indicated that placentally derived
cell-free nucleic acids were associated with micro-
debris released by syncytiotrophoblast turnover [32].
Placental microdebris could trigger neutrophil extracel-
lular trap (NET) generation by the extracellular extrusion
of their nuclear DNA. NETs have been found in greater
quantities in pre-eclamptic placentae than in those
with normal healthy deliveries. The role NETs play in the
underlying aetiology of pre-eclampsia awaits further
clarification.
SSc
In the past, pregnant SSc patients were thought to be at
high risk for poor fetal and maternal outcome. In a recent
Italian study considered the largest up to now, 17 centres
prospectively followed 70 pregnancies in 62 women with
SSc. Mean age at conception was 30.9 years, and duration
of disease 56 months; diffuse disease was present in
47% of women. The control group was a cohort of
111 women with SLE followed in the same period at
four centres.
Pregnancy losses occurred in 4% of SSc women vs
15% of SLE women (P= 0.03); with prematurity as the
most prominent adverse outcome in SSc (25% in SSc
vs 17% in SLE); pre-eclampsia and hypertension occurred
more frequently in SLE (1.5 vs 7% SLE).
Pregnancy outcomes were similar in limited and diffuse
SSc and were not correlated with disease activity. SSc
skin involvement remained stable in 69% of women, RP
improved in 40%, oesophageal reflux worsened in 24%,
spirometry remained stable in 72% and echocardiography
was stable in 98%. No renal crisis was observed, but
pulmonary hypertension developed in one woman. The
study confirms that women with SSc can have uncompli-
cated, successful pregnancies, provided the disease is
stable and organ damage mild. High-risk pregnancy
management should be standard, because of the high
frequency of prematurity [33].
Vasculitis
Improvement in diagnosis of primary systemic vasculi-
tides has led to an earlier detection and treatment with
the consequent improvement of survival rate as well as
quality of life. For these reasons, reproduction is becom-
ing an important issue in patients with vasculitides. Data
on pregnancy in patients with systemic vasculitides are
scarce due to their low incidence, low female : male ratio
or their frequent disease onset after childbearing age.
However, patients with Behc¸et disease tend to improve
during pregnancy and are at low risk for preterm delivery,
fetal and obstetric complications. Maternal and fetal
outcome has been satisfactory in most patients with
Takayasu arteritis, WG and ChurgStrauss syndrome
when the disease activity was well controlled [34] (Table 1).
An assessment of microscopic polyangitis or PAN during
pregnancy is not possible due to the few case reports
published. Patients with active vasculitis at conception or
disease onset during pregnancy are at increased risk for
adverse pregnancy outcomes. The severity of the initial
www.rheumatology.oxfordjournals.org 661
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manifestations of vasculitis does not predict the activity of
the disease during pregnancy. A disease flare during preg-
nancy or post-partum is possible even when the vasculitis
was quiescent at conception. Frequent control during
pregnancy and post-partum is therefore mandatory.
Preconceptional counselling of high-risk
pregnancies
Co-ordinated medical/obstetric care is essential to
maximize the chance of successful pregnancy outcome
in women with vasculitis or CTDs [35]. Optimum disease
control and preferably remission or low disease activity
before pregnancy is the requirement for good outcomes.
Previous complicated pregnancies, renal disease, irre-
versible organ damage, anti-Ro/SSA and aPL and treat-
ment with high doses of glucocorticoids increase the risk
of complications. Pregnancy is contraindicated in women
with symptomatic pulmonary hypertension, heart failure,
severe restrictive pulmonary disease, severe chronic renal
failure, recent high disease activity and recent arterial
thrombosis.
During pregnancy, HCQ, low-dose glucocorticoids
and AZA can be safely used. Pulse i.v. steroids can be
given in cases of severe SLE or vasculitis flares. CYC,
MTX and MMF are contraindicated during pregnancy
and lactation [36].
Follow-up of children
Apart from neonatal and perinatal disease induced by
aPLs or Ro/SSA antibodies, very little information about
the long-term outcome of children born to mothers with
SLE or APS exists. A prospective study on the long-term
outcome of children up to the age of 17 years born to
mothers with SLE is now in progress [37]. In a follow-up
study of 38 children born after the diagnosis of APS,
delayed milestones or developmental abnormalities were
reported in 9 (23%) compared with a national average
of 4%. Attention-deficit disorders were found in three
children and dyslexia was identified in two males.
Children born to APS mothers are more likely to be de-
livered preterm, have low birthweights and demonstrate
neurological developmental abnormalities than those born
to normal mothers. Neuro-developmental abnormalities
result mostly from preterm birth rather than from the
disease or medications. An increased rate of learning dis-
abilities has been found in children of SLE mothers and
women with aPL [38]. Genetic factors can be inherited and
may predispose to autoimmunity in the children later
in life.
Another concern is the long-term outcome of children
exposed to immunosuppressive drugs in utero. Several
studies assessed humoral and cellular immune responses
of children exposed to glucocorticoids alone or in
combination with AZA or ciclosporin or high-dose dexa-
methasone for anti-Ro/SSA-associated CHB [39, 40]. No
significant differences from matched controls were found.
Children exposed to HCQ during pregnancy and lactation
showed no signs of ophthalmic or ototoxic toxicity [33].
The follow-up of children exposed to TNF blockers
during pregnancy is still too short to draw definite conclu-
sions on safety.
In Brescia, 10 children exposed to etanercept during
18 weeks of pregnancy were followed up for a mean
period of 11 months (range 145 months). No particular
complications at birth or developmental abnormalities
were observed. In conclusion, follow-up of children
exposed to immunosuppressive drugs needs to be
constantly updated in order to support existing data on
a growing number of cases.
Fertility
Infertility affects 1015% of all couples, and is higher in
male and female patients with rheumatic disease [41].
Normal values of sperm parameters were published by
the World Health Organization (WHO) in 1992 and 1999
and, for morphology, by Kruger (1998). However, nearly
all reference values (especially morphology) have been
questioned. A Swiss study of proven fertile men whose
partners were pregnant at the time of study inclusion
showed high variability of several sperm parameters,
especially morphology [39].
Similar results were found in young Swiss recruits [42].
This shows that there are wide ranges for most sperm
parameters and no diagnosis of male infertility can
be made because of a single abnormal parameter. A
combination of several semen criteria is more predictive.
A Brazilian study revealed impaired testicular and
sexual function in 35 male SLE patients [43]. SLE patients
had lower median testicular volume in both testes
(P= 0.003 and P= 0.004), total sperm count (P= 0.002)
and total motile sperm count (P= 0.004) compared with
35 healthy controls.
A lower median sperm concentration (P= 0.0001), total
sperm count (P= 0.0001), total motility sperm count
(P= 0.0001), sperm motility (P= 0.004) and Kruger normal
sperm forms were found in SLE patients under i.v. CYC
(IVCYC) therapy (P= 0.038) compared with patients
without this treatment [43].
Almost a quarter of SLE patients had Sertoli cell
dysfunction according to low serum inhibin B, and the
serum level was lower in SLE patients treated with
IVCYC compared with those without this therapy
(P= 0.031). Further evaluation of the 26 SLE patients
with normal inhibin B and FSH levels revealed that
medians of inhibin B : FSH ratio were lower in SLE patients
with oligozoospermia compared with normozoospermia
(P= 0.004) [44].
The inhibin:FSH ratio was also lower in SLE patients
treated with IVCYC than those without this therapy
(P= 0.04). Furthermore, the frequencies of sexual/erectile
dysfunction were significantly higher in SLE vs controls
(P= 0.0001) [44].
These are the first studies to identify sexual/erectile and
gonadal dysfunction in male SLE patients. A multidiscip-
linary approach is essential in order to offer preventive
measures, including sperm cryopreservation before
IVCYC therapy, for these patients.
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Conclusion
Some previously accepted paradigms such as spontan-
eous improvement for the majority of pregnant women
with RA and predominantly unfavourable pregnancy out-
comes in SLE, APS and SSc have lately been challenged.
Due to an increasing recognition of risk factors and an
interdisciplinary approach in monitoring pregnancy, most
women with autoimmune rheumatic diseases can have
successful pregnancies, provided pregnancy is planned
and occurs after a prolonged period of remission or low
disease activity. Poor disease control and flares in preg-
nancy may result in low birthweight and prematurity, and
these factors are more likely to cause short- and long-
term adverse outcomes in the offspring than the maternal
disease or the medication used during pregnancy.
Problems remain in patients not responding to standard
therapy or with life-threatening organ manifestations.
Some areas, previously neglected, such as fertility in
male patients and long-term effects of maternal disease
in offspring are now under more intense investigation.
Follow-up of children during childhood and adoles-
cence will answer questions related to possible adverse
long-term effects of maternal disease or therapy during
pregnancy. Awareness of the risk for learning disabilities
in children of SLE and APS mothers can assist in early
recognition and proper management.
In addition, reproduction problems need to be ad-
dressed both in female and male patients, risk factors
for adverse outcome of pregnancy or for offspring must
be analysed and appropriate counselling and skilled
management be given.
In conclusion, expert surveillance ensures a safe
pregnancy for the majority of women with autoimmune
rheumatic diseases.
Rheumatology key messages
. Female gonadal hormones have an impact on the
aetiology and course of chronic inflammatory/auto-
immune diseases.
. Use of OCPs and pregnancy can modify disease
symptoms.
. Pre-pregnancy planning and interdisciplinary moni-
toring throughout pregnancy ensures a successful
pregnancy outcome for most patients.
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